VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer
| Title: | VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer |
|---|---|
| Authors: | Chionh, FionaAff1; Gebski, ValAff2; Al-Obaidi, Sheren J.Aff1; Mooi, Jennifer K.Aff1; Bruhn, Maressa A.Aff3; Lee, Chee K.Aff2; Chüeh, Anderly C.Aff1, Aff4, Aff5; Williams, David S.Aff1, Aff6, Aff7, Aff8; Weickhardt, Andrew J.Aff1; Wilson, KateAff2; Scott, Andrew M.Aff1, Aff6, Aff9; Simes, JohnAff2; Hardingham, Jennifer E.Aff3, Aff10; Price, Timothy J.Aff3, Aff10; Mariadason, John M.Aff1, Aff6, IDs4159802103952y_cor15; Tebbutt, Niall C.Aff1, Aff11, Aff12, IDs4159802103952y_cor16 |
| Source: | Scientific Reports. 12(1) |
| Database: | Springer Nature Journals |